Webinar notes
Some points of consideration #COVIDー19 #vaccine development:
Which populations should be studied first?
Which endpoints will be clinically meaningful (or not) for clinical trials
Viral Load Testing: e.g., its utility in upper vs lower resp tract
1 of 4
Some points of consideration #COVIDー19 #vaccine development:
Which populations should be studied first?
Which endpoints will be clinically meaningful (or not) for clinical trials
Viral Load Testing: e.g., its utility in upper vs lower resp tract
1 of 4
https://twitter.com/EpidemicsEthics/status/1260205618754998273
@ArthurCaplan is sceptical about a #COVID19 vaccine in the next 12 months, due to many challenges such as:
- vaccine efficacy
- distribution issues (WHO vs US; where the initial batches of vaccine go. could set off international disputes)
- many vaccines require > 1 shot
2 of 4
- vaccine efficacy
- distribution issues (WHO vs US; where the initial batches of vaccine go. could set off international disputes)
- many vaccines require > 1 shot
2 of 4
If you are waiting for ppl to get naturally infected by #COVID19 & the virus ebbs and flows, you will wait for a long time.
@ArthurCaplan discussed *human challenge studies* (ethically controversial, too) as an alternative to standard #COVID19 vaccine studies.
3 of 4
@ArthurCaplan discussed *human challenge studies* (ethically controversial, too) as an alternative to standard #COVID19 vaccine studies.
3 of 4
Challenge studies will be conducted on younger healthier patients. Unlikely to recruit elderly/those with weaker immune system in #COVID19 #challengestudies -> efficacy issues (?)
Scientists would be sceptical to see an effective response in 65+ group in standard studies, anyway
Scientists would be sceptical to see an effective response in 65+ group in standard studies, anyway
@threadreaderapp unroll @EpidemicsEthics
• • •
Missing some Tweet in this thread? You can try to
force a refresh
